Summary & Overview
HCPCS J0220: Injection, alglucosidase alfa, 10 mg
HCPCS Level II code J0220 denotes the injection of alglucosidase alfa in 10 mg units, an enzyme replacement therapy used in clinical settings that provide parenteral infusion. Nationally, accurate reporting of this HCPCS Level II code matters for clinical documentation, payer adjudication, and aggregate tracking of specialty drug utilization.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of what the code represents, the typical sites of service for administration, and payer scope. The publication provides benchmarks where available, notes of relevant policy updates affecting coverage and billing for specialty infusions, and clinical context about why alglucosidase alfa administration is billed with this unit-based HCPCS Level II code.
The piece is intended to help billing managers, revenue cycle professionals, and clinicians understand coding semantics, typical reimbursement pathways, and the operational contexts in which J0220 is used. Data not provided in the input are identified explicitly.
Billing Code Overview
HCPCS Level II code J0220 represents the injection of alglucosidase alfa, 10 mg, not otherwise specified. This code is used to report administration of the enzyme replacement therapy alglucosidase alfa in 10 mg units.
-
Service type: Parenteral infusion/injection of enzyme replacement therapy
-
Typical site of service: Infusion center, outpatient hospital infusion unit, or physician office infusion setting
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient with confirmed Pompe disease (acid maltase deficiency) or late-onset lysosomal storage disorder presents for enzyme replacement therapy with intravenous alglucosidase alfa. Typical patients are enrolled in long-term infusion programs and arrive to an outpatient infusion center, hospital outpatient department, or occasionally a skilled nursing facility for scheduled dosing. The clinical workflow includes pre-infusion nursing assessment (vital signs, weight, medication reconciliation, review of recent infusion reactions), verification of physician orders and dose calculation based on weight, preparation of J0220 (alglucosidase alfa) by pharmacy under sterile conditions, and administration via peripheral or central IV access over the recommended infusion time with continuous monitoring for infusion-related reactions. Post-infusion observation occurs per protocol; documentation includes drug name, dose in milligrams, lot number, administration route, infusion start and stop times, and any adverse reactions and interventions. Billing uses HCPCS code J0220 reported per 10 mg unit with appropriate diagnosis linkage and applicable modifiers for circumstances such as multiple procedures, emergency situation, or suspension of care.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier / default |